Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Company Overview

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Key Stats

• Today's Range: $5.13 to $5.35
• 50-Day Range: $4.74 to $5.69
• 52-Week Range: $3.71 to $8.74
• Volume: 670,947 shs
• Average Volume: 714,166 shs
• Market Capitalization: $143.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.75
• Consensus Rating: Moderate Buy

Unicycive Therapeutics Stock Analysis - MarketRank™

Unicycive Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 379th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Unicycive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Unicycive Therapeutics has a consensus price target of $18.75, representing about 264.1% upside from its current price of $5.15.

Amount of Analyst Coverage

Unicycive Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($1.17) to $2.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Unicycive Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Unicycive Therapeutics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Unicycive Therapeutics has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.94% of the float of Unicycive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Unicycive Therapeutics has a short interest ratio ("days to cover") of 5.85.

Change versus previous month

Short interest in Unicycive Therapeutics has recently decreased by 5.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Unicycive Therapeutics does not currently pay a dividend.

Dividend Growth

Unicycive Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.01

News Sentiment

Unicycive Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for Unicycive Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.03% of the stock of Unicycive Therapeutics is held by insiders.

Percentage Held by Institutions

40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/15/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/15/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:UNCY
• CIK: 1766140
• Web: www.unicycive.com
• Phone: 650-351-4495
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Unicycive Therapeutics: $18.75
• High Price Target: $25.00
• Low Price Target: $15.00
• Potential Upside/Downside: +264.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -91.50%
• Return on Assets: -61.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.81
• Quick Ratio: 3.81

Sales & Book Value

• Annual Sales: $680 thousand
• Price / Sales: 210.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 3.65

Miscellaneous

• Outstanding Shares: 27,850,000
• Free Float: 26,175,000
• Market Cap: $143.43 million
• Optionable: Not Optionable
• Beta: 1.79